TW201028420A - 6-cycloamino-2,3-dipyridylimidazo[1,2-b]-pyridazine derivatives, preparation and therapeutic use thereof - Google Patents

6-cycloamino-2,3-dipyridylimidazo[1,2-b]-pyridazine derivatives, preparation and therapeutic use thereof Download PDF

Info

Publication number
TW201028420A
TW201028420A TW098143412A TW98143412A TW201028420A TW 201028420 A TW201028420 A TW 201028420A TW 098143412 A TW098143412 A TW 098143412A TW 98143412 A TW98143412 A TW 98143412A TW 201028420 A TW201028420 A TW 201028420A
Authority
TW
Taiwan
Prior art keywords
group
alkyl
formula
compound
doc
Prior art date
Application number
TW098143412A
Other languages
English (en)
Chinese (zh)
Inventor
Matthieu Barrague
Yulin Chiang
Pascal George
William A Metz
Frederic Puech
Mireille Sevrin
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of TW201028420A publication Critical patent/TW201028420A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW098143412A 2008-12-19 2009-12-17 6-cycloamino-2,3-dipyridylimidazo[1,2-b]-pyridazine derivatives, preparation and therapeutic use thereof TW201028420A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0807257A FR2940284B1 (fr) 2008-12-19 2008-12-19 Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
US13965208P 2008-12-22 2008-12-22

Publications (1)

Publication Number Publication Date
TW201028420A true TW201028420A (en) 2010-08-01

Family

ID=40848284

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098143412A TW201028420A (en) 2008-12-19 2009-12-17 6-cycloamino-2,3-dipyridylimidazo[1,2-b]-pyridazine derivatives, preparation and therapeutic use thereof

Country Status (12)

Country Link
EP (1) EP2385946A1 (pt)
JP (1) JP2012512853A (pt)
KR (1) KR20110095964A (pt)
CN (1) CN102325773A (pt)
AR (1) AR074685A1 (pt)
AU (1) AU2009329427A1 (pt)
BR (1) BRPI0923182A2 (pt)
CA (1) CA2747365A1 (pt)
FR (1) FR2940284B1 (pt)
SG (1) SG172181A1 (pt)
TW (1) TW201028420A (pt)
WO (1) WO2010070238A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100533A1 (en) 2012-12-21 2014-06-26 Bristol-Myers Squibb Company NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS
US9475817B2 (en) 2012-12-21 2016-10-25 Bristol-Myers Squibb Company Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
ES2728932T3 (es) 2014-01-09 2019-10-29 Intra Cellular Therapies Inc Compuestos orgánicos
US9956220B2 (en) 2014-06-19 2018-05-01 Bristol-Myers Squibb Company Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors
EP3921317B1 (en) 2019-02-07 2023-08-02 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors
EP4188928B1 (en) 2020-07-29 2024-07-24 Bayer Aktiengesellschaft Substituted 1 h-pyrrolo[3,2-b]pyridin compounds and methods of use thereof
CA3235146A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
EP4469457A4 (en) * 2022-01-27 2026-01-21 Broad Inst Inc CSNK1 SUBSTITUTE HETEROCYCLIC INHIBITORS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001333A1 (en) * 1987-08-07 1989-02-23 The Australian National University IMIDAZO[1,2-b]PYRIDAZINES
AR041292A1 (es) * 2002-09-19 2005-05-11 Schering Corp Pirazolopiridinas como inhibidores de quinasa dependientes de ciclina
WO2004058769A2 (en) * 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Triazolopyridazines as protein kinases inhibitors
ATE428711T1 (de) 2003-12-11 2009-05-15 Aventis Pharma Inc Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3- cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i- epsilon
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
WO2006070943A1 (ja) * 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
FR2918061B1 (fr) * 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
FR2918986B1 (fr) * 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
FR2940284B1 (fr) 2011-02-18
EP2385946A1 (fr) 2011-11-16
CN102325773A (zh) 2012-01-18
SG172181A1 (en) 2011-07-28
AR074685A1 (es) 2011-02-02
KR20110095964A (ko) 2011-08-25
AU2009329427A1 (en) 2011-07-07
JP2012512853A (ja) 2012-06-07
FR2940284A1 (fr) 2010-06-25
BRPI0923182A2 (pt) 2019-09-24
CA2747365A1 (fr) 2010-06-24
WO2010070238A1 (fr) 2010-06-24

Similar Documents

Publication Publication Date Title
JP5431319B2 (ja) ６−シクロアミノ−３−（ピリダジン−４−イル）イミダゾ［１，２−ｂ］−ピリダジンおよびこれらの誘導体、これらの調製および治療上の用途
JP5537424B2 (ja) ６−シクロアミノ−３−（ピリジン−４−イル）イミダゾ［１，２−ｂ］ピリダジン誘導体、これらの調製およびこれらの治療的使用
JP4845736B2 (ja) プロテインキナーゼ阻害剤
TWI553005B (zh) 經取代之酞－１（２ｈ）－酮衍生物
TW201028420A (en) 6-cycloamino-2,3-dipyridylimidazo[1,2-b]-pyridazine derivatives, preparation and therapeutic use thereof
CN103570725B (zh) 哌嗪并三唑类化合物及其制备方法和用途
CN103848785B (zh) 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
DK2698372T3 (en) New imidazo-oxazinforbindelse or salt thereof.
WO2022222965A1 (zh) 吡啶衍生物及其在医药上的应用
CN108570059A (zh) 一种具有prmt5抑制活性的化合物及其制备和应用
TW201011028A (en) 2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives, their preparation and their therapeutic use
CN101851237B (zh) 一种螺环化合物及其制备方法和应用
CN120112532A (zh) Parg抑制性化合物
CN111909181A (zh) 一类泛素化特异性蛋白酶抑制剂及其制备方法与应用
CN103833756B (zh) 一类哒嗪酮类化合物及其制备方法和用途
TW201028419A (en) Derivatives of 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo[1,2-b]-pyridazine and 6-cycloamino-2-furanyl-3-(pyridin-4-yl)imidazo[1,2-b]-pyridazine, preparation thereof and therapeutic use thereof
Akué-Gédu et al. Synthesis, Pim kinase inhibitory potencies and in vitro antiproliferative activities of diversely substituted pyrrolo [2, 3-a] carbazoles
CN103570730A (zh) 具有桥环结构的稠环哒嗪酮类化合物及其制备方法和用途
TW201033209A (en) 6-cycloamino-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof
WO2021249319A1 (zh) 三环化合物、药物组合物及其应用
CN114751899B (zh) 一种二芳基脲类mTOR激酶抑制剂及其药物组合物和应用
CN114853752B (zh) Btk抑制剂吡啶并杂环类化合物的制备及其应用
CN101857594A (zh) 一种四氢吡啶并吲哚类化合物及其制备方法和应用
KR101532850B1 (ko) 항암 활성을 갖는 벤즈아미드 유도체 및 이의 제조 방법 및 용도
CN116425743A (zh) 一种作为PI3Kα激酶抑制剂的苯并杂环类化合物及其制备方法与应用